{"database": "lobbying", "table": "lobbying_activities", "rows": [[3490149, "8f3a5f6e-7854-4522-968c-2e8a571aefd1", "Q4", "DLA PIPER LLP (US)", 76855, "BIOTECHNOLOGY INNOVATION ORGANIZATION", 2025, "fourth_quarter", "MED", "Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. H.R. 946, ORPHAN Cures Act. H.R. 1262/S. 932, The Give Kids a Chance Act. IRA implementation. 340B. Orphan drugs. Supply chain. Vaccine policy.", "Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE", 60000, null, 0, 0, "2026-01-16T15:13:09-05:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["3490149"], "units": {}, "query_ms": 0.28142507653683424, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}